News archive
Showing 705 results
June 2025
-
Story Education and Awareness
How Katy, a Patient Turned Advocate, Found Her Purpose
Katy Shusta is helping to rewrite the narrative around hidradenitis suppurativa (HS) – a painful skin condition impacting as many as one in 100 people worldwide.1
-
Media Release
Novartis Pluvicto™ demonstrates statistically significant and clinically meaningful rPFS benefit in patients with PSMA-positive metastatic hormone-sensitive prostate cancer
Ad hoc announcement pursuant to Art. 53 LR At interim analysis, PSMAddition trial met its primary endpoint showing statistically significant and clinically meaningful benefit for Pluvicto™ plus… -
Media Release
Novartis Kisqali® reduces risk of recurrence in younger patients with early breast cancer in NATALEE subgroup analysis
33% reduction in relative risk of invasive disease observed in pre-menopausal early breast cancer (EBC) patients receiving Kisqali in 1-year post-treatment analysis1 Tolerability remained…
May 2025
-
Story Education and Awareness
Introducing the GARAGE by iLab: Behind the Scenes at Our New Innovation Hub
Learn about the launch of our new state-of-the-art space, built to accelerate innovation from the inside out and provide new solutions for employees, partners and ultimately, our patients.
-
Story Hope
Exploring the Future of Cancer Care at the Time100 Health Impact Dinner
What does it mean to be diagnosed – or living with – cancer today? Novartis US President Victor Bultó offers insights into the changing oncology landscape. -
Story Discovery
How We’re Reimagining Cancer Care for the Next Generation Patient
-
Story Education and Awareness
Addressing Elevated Lipoprotein(a): The Importance of Testing At-Risk Patients
Elevated Lp(a) is a unique and genetically determined condition that can increase risk for ASCVD1. Read on to learn more about patient populations at risk.
-
Media Release
New Novartis data at ASCO and EHA showcase momentum of pioneering portfolio with promising pipeline
NATALEE subanalysis evaluates Kisqali in pre-menopausal early breast cancer patients, amid rising diagnosis rates in younger patients Pluvicto analysis and Scemblix ASC4START primary… -
Story Education and Awareness
Autoimmune Diseases Disproportionately Impact Women — Here’s Why That Matters
Novartis is raising awareness about the disproportionate impact and often invisible burden of autoimmune diseases on women.
April 2025
-
Media Release
Novartis plans to expand its US-based manufacturing and R&D footprint with a total investment of $23B over the next 5 years
Expanded US manufacturing and R&D presence with investment in 10 facilities, including 7 brand new facilities With new manufacturing capacity, Novartis will be able to produce 100% of its… -
Media Release
Novartis receives FDA accelerated approval for Vanrafia® (atrasentan), the first and only selective endothelin A receptor antagonist for proteinuria reduction in primary IgA nephropathy (IgAN)
Vanrafia can be seamlessly added to supportive care in IgAN and used as a foundational therapy with no requirement for a REMS (Risk Evaluation Mitigation Strategy) program1 Phase III data showed…